

REFERENCES

- [1] Festi, D., R. Schiumerini, L.H. Eusebi, G. Marasco, M. Taddia, and A. Colecchia, Gut microbiota and metabolic syndrome. *World J Gastroenterol.* 2014; 20(43):16079-94.
- [2] Everard, A. and P.D. Cani, Diabetes, obesity and gut microbiota. *Best Pract Res Clin Gastroenterol.* 2013; 27(1):73-83.
- [3] Tremaroli, V. and F. Backhed, Functional interactions between the gut microbiota and host metabolism. *Nature.* 2012; 489(7415):242-9.
- [4] Ley, R.E., P.J. Turnbaugh, S. Klein, and J.I. Gordon, Microbial ecology: Human gut microbes associated with obesity. *Nature.* 2006; 444(7122):1022-1023.
- [5] Zhao, L., The gut microbiota and obesity: from correlation to causality. *Nat Rev Microbiol.* 2013; 11(9):639-47.
- [6] Apaijai, N., H. Pintana, S.C. Chattipakorn, and N. Chattipakorn, Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats. *Br J Pharmacol.* 2013; 169(5):1048-57.
- [7] Sender, R., S. Fuchs, and R. Milo, Revised estimates for the number of human and bacteria cells in the body. *bioRxiv.* 2016.
- [8] Donaldson, G.P., S.M. Lee, and S.K. Mazmanian, Gut biogeography of the bacterial microbiota. *Nat Rev Microbiol.* 2016; 14(1):20-32.
- [9] DiBaise, J.K., D.N. Frank, and R. Mathur, Impact of the Gut Microbiota on the Development of Obesity: Current Concepts. *The American Journal of Gastroenterology Supplements.* 2012; 1(1):22-27.

- [10] Guarner, F. and J.R. Malagelada, Gut flora in health and disease. *Lancet*. 2003; 361(9356):512-9.
- [11] Skaar, E.P. and M. Raffatellu, Metals in infectious diseases and nutritional immunity. *Metallomics*. 2015; 7(6):926-8.
- [12] Sassone-Corsi, M. and M. Raffatellu, No vacancy: how beneficial microbes cooperate with immunity to provide colonization resistance to pathogens. *J Immunol*. 2015; 194(9):4081-7.
- [13] Winer, D.A., H. Luck, S. Tsai, and S. Winer, The Intestinal Immune System in Obesity and Insulin Resistance. *Cell Metab*. 2016; 23(3):413-26.
- [14] Thaiss, C.A., M. Levy, J. Suez, and E. Elinav, The interplay between the innate immune system and the microbiota. *Curr Opin Immunol*. 2014; 26:41-8.
- [15] Abreu, M.T., Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. *Nat Rev Immunol*. 2010; 10(2):131-44.
- [16] Round, J.L. and S.K. Mazmanian, Inducible Foxp3(+) regulatory T-cell development by a commensal bacterium of the intestinal microbiota. *Proceedings of the National Academy of Sciences of the United States of America*. 2010; 107(27):12204-12209.
- [17] Vijay-Kumar, M., J.D. Aitken, F.A. Carvalho, T.C. Cullender, S. Mwangi, S. Srinivasan, et al., Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. *Science*. 2010; 328(5975):228-31.
- [18] Bouskra, D., C. Brezillon, M. Berard, C. Werts, R. Varona, I.G. Boneca, et al., Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis. *Nature*. 2008; 456(7221):507-10.
- [19] Shoelson, S.E. and A.B. Goldfine, Getting away from glucose: fanning the flames of obesity-induced inflammation. *Nat Med*. 2009; 15(4):373-4.

- [20] Backhed, F., H. Ding, T. Wang, L.V. Hooper, G.Y. Koh, A. Nagy, et al., The gut microbiota as an environmental factor that regulates fat storage. *Proc Natl Acad Sci U S A*. 2004; 101(44):15718-23.
- [21] Turnbaugh, P.J., R.E. Ley, M.A. Mahowald, V. Magrini, E.R. Mardis, and J.I. Gordon, An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature*. 2006; 444(7122):1027-31.
- [22] Cani, P.D. and N.M. Delzenne, The gut microbiome as therapeutic target. *Pharmacol Ther*. 2011; 130(2):202-12.
- [23] Morelli, L. and L. Capurso, FAO/WHO Guidelines on Probiotics: 10 Years Later. *Journal of Clinical Gastroenterology*. 2012; 46.
- [24] Patel, R. and H.L. DuPont, New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics. *Clin Infect Dis*. 2015; 60 Suppl 2:S108-21.
- [25] Krumbeck, J.A., M.X. Maldonado-Gomez, A.E. Ramer-Tait, and R.W. Hutkins, Prebiotics and synbiotics: dietary strategies for improving gut health. *Curr Opin Gastroenterol*. 2016; 32(2):110-9.
- [26] Wu, H., V. Tremaroli, and F. Backhed, Linking Microbiota to Human Diseases: A Systems Biology Perspective. *Trends Endocrinol Metab*. 2015; 26(12):758-70.
- [27] Walsh, C.J., C.M. Guinane, P.W. O'Toole, and P.D. Cotter, Beneficial modulation of the gut microbiota. *FEBS Lett*. 2014; 588(22):4120-30.
- [28] Fak, F. and F. Backhed, *Lactobacillus reuteri* prevents diet-induced obesity, but not atherosclerosis, in a strain dependent fashion in *Apoe*^{-/-} mice. *PLoS One*. 2012; 7(10):e46837.
- [29] Stsepetova, J., E. Sepp, H. Kolk, K. Loivukene, E. Songisepp, and M. Mikelsaar, Diversity and metabolic impact of intestinal *Lactobacillus* species in healthy adults and the elderly. *Br J Nutr*. 2011; 105(8):1235-44.

- [30] Cox, A.J., N.P. West, and A.W. Cripps, Obesity, inflammation, and the gut microbiota. *Lancet Diabetes Endocrinol.* 2014.
- [31] Cani, P.D., J. Amar, M.A. Iglesias, M. Poggi, C. Knauf, D. Bastelica, et al., Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes.* 2007; 56(7):1761-72.
- [32] Ding, S., M.M. Chi, B.P. Scull, R. Rigby, N.M. Schwerbrock, S. Magness, et al., High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. *PLoS One.* 2010; 5(8):e12191.
- [33] Ley, R.E., F. Backhed, P. Turnbaugh, C.A. Lozupone, R.D. Knight, and J.I. Gordon, Obesity alters gut microbial ecology. *Proc Natl Acad Sci U S A.* 2005; 102(31):11070-5.
- [34] Kim, K.A., W. Gu, I.A. Lee, E.H. Joh, and D.H. Kim, High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. *PLoS One.* 2012; 7(10):e47713.
- [35] de La Serre, C.B., C.L. Ellis, J. Lee, A.L. Hartman, J.C. Rutledge, and H.E. Raybould, Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. *Am J Physiol Gastrointest Liver Physiol.* 2010; 299(2):G440-8.
- [36] Cani, P.D., R. Bibiloni, C. Knauf, A. Waget, A.M. Neyrinck, N.M. Delzenne, et al., Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. *Diabetes.* 2008; 57(6):1470-81.
- [37] Schulz, M.D., C. Atay, J. Heringer, F.K. Romrig, S. Schwitalla, B. Aydin, et al., High-fat-diet-mediated dysbiosis promotes intestinal carcinogenesis independently of obesity. *Nature.* 2014; 514(7523):508-12.
- [38] Park, H.J., S.E. Lee, H.B. Kim, R.E. Isaacson, K.W. Seo, and K.H. Song, Association of Obesity with Serum Leptin, Adiponectin, and Serotonin and

- Gut Microflora in Beagle Dogs. *J Vet Intern Med.* 2014.
- [39] Kwon, H. and J.E. Pessin, Adipokines mediate inflammation and insulin resistance. *Front Endocrinol (Lausanne).* 2013; 4:71.
- [40] Belizario, J.E. and M. Napolitano, Human microbiomes and their roles in dysbiosis, common diseases, and novel therapeutic approaches. *Front Microbiol.* 2015; 6:1050.
- [41] Ermolenko, E., L. Gromova, Y. Borschev, A. Voikova, A. Karaseva, K. Ermolenko, et al., Influence of different probiotic lactic Acid bacteria on microbiota and metabolism of rats with dysbiosis. *Biosci Microbiota Food Health.* 2013; 32(2):41-9.
- [42] Lecomte, V., N.O. Kaakoush, C.A. Maloney, M. Raipuria, K.D. Huinao, H.M. Mitchell, et al., Changes in gut microbiota in rats fed a high fat diet correlate with obesity-associated metabolic parameters. *PLoS One.* 2015; 10(5):e0126931.
- [43] Cox, A.J., N.P. West, and A.W. Cripps, Obesity, inflammation, and the gut microbiota. *Lancet Diabetes Endocrinol.* 2015; 3(3):207-15.
- [44] Radilla-Vazquez, R.B., I. Parra-Rojas, N.E. Martinez-Hernandez, Y.F. Marquez-Sandoval, B. Illades-Aguilar, and N. Castro-Alarcon, Gut Microbiota and Metabolic Endotoxemia in Young Obese Mexican Subjects. *Obes Facts.* 2016; 9(1):1-11.
- [45] Ghanim, H., S. Abuaysheh, C.L. Sia, K. Korzeniewski, A. Chaudhuri, J.M. Fernandez-Real, et al., Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. *Diabetes Care.* 2009; 32(12):2281-7.
- [46] Gregor, M.F. and G.S. Hotamisligil, Inflammatory mechanisms in obesity. *Annu Rev Immunol.* 2011; 29:415-45.

- [47] Hotamisligil, G.S., Inflammation and metabolic disorders. *Nature*. 2006; 444(7121):860-7.
- [48] Osborn, O. and J.M. Olefsky, The cellular and signaling networks linking the immune system and metabolism in disease. *Nat Med*. 2012; 18(3):363-74.
- [49] Delzenne, N.M., A.M. Neyrinck, F. Backhed, and P.D. Cani, Targeting gut microbiota in obesity: effects of prebiotics and probiotics. *Nat Rev Endocrinol*. 2011; 7(11):639-646.
- [50] West, C.E., H. Renz, M.C. Jenmalm, A.L. Kozyrskyj, K.J. Allen, P. Vuillermin, et al., The gut microbiota and inflammatory noncommunicable diseases: associations and potentials for gut microbiota therapies. *J Allergy Clin Immunol*. 2015; 135(1):3-13; quiz 14.
- [51] Stenman, L.K., R. Burcelin, and S. Lahtinen, Establishing a causal link between gut microbes, body weight gain and glucose metabolism in humans - towards treatment with probiotics. *Benef Microbes*. 2015:1-12.
- [52] Delzenne, N.M. and P.D. Cani, Nutritional modulation of gut microbiota in the context of obesity and insulin resistance: Potential interest of prebiotics. *International Dairy Journal*. 2010; 20(4):277-280.
- [53] Flynn, S., D. van Sinderen, G.M. Thornton, H. Holo, I.F. Nes, and J.K. Collins, Characterization of the genetic locus responsible for the production of ABP-118, a novel bacteriocin produced by the probiotic bacterium *Lactobacillus salivarius* subsp. *salivarius* UCC118. *Microbiology*. 2002; 148(Pt 4):973-84.
- [54] Madsen, K.L., J.S. Doyle, L.D. Jewell, M.M. Tavernini, and R.N. Fedorak, *Lactobacillus* species prevents colitis in interleukin 10 gene-deficient mice. *Gastroenterology*. 1999; 116(5):1107-14.
- [55] Kaila, M., E. Isolauri, E. Soppi, E. Virtanen, S. Laine, and H. Arvilommi, Enhancement of the circulating antibody secreting cell response in human diarrhea by a human *Lactobacillus* strain. *Pediatr Res*. 1992; 32(2):141-4.

- [56] Wang, J., H. Tang, C. Zhang, Y. Zhao, M. Derrien, E. Rocher, et al., Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice. *Isme j.* 2015; 9(1):1-15.
- [57] Kadooka, Y., M. Sato, K. Imaizumi, A. Ogawa, K. Ikuyama, Y. Akai, et al., Regulation of abdominal adiposity by probiotics (*Lactobacillus gasseri* SBT2055) in adults with obese tendencies in a randomized controlled trial. *Eur J Clin Nutr.* 2010; 64(6):636-43.
- [58] Wang, L.X., K. Liu, D.W. Gao, and J.K. Hao, Protective effects of two *Lactobacillus plantarum* strains in hyperlipidemic mice. *World J Gastroenterol.* 2013; 19(20):3150-6.
- [59] Sasithorn Sirilun, C.C., Duangporn Kantachote and Plearnpis Luxananil, Characterisation of non human origin probiotic *Lactobacillus plantarum* with cholesterol-lowering property. *Afr J Microbiol Res.* 2010; 4(10):994-1000.
- [60] Salaj, R., J. Stofilova, A. Soltesova, Z. Hertelyova, E. Hijova, I. Bertkova, et al., The effects of two *Lactobacillus plantarum* strains on rat lipid metabolism receiving a high fat diet. *ScientificWorldJournal.* 2013; 2013:135142.
- [61] Wu, C.C., W.L. Weng, W.L. Lai, H.P. Tsai, W.H. Liu, M.H. Lee, et al., Effect of *Lactobacillus plantarum* Strain K21 on High-Fat Diet-Fed Obese Mice. *Evid Based Complement Alternat Med.* 2015; 2015:391767.
- [62] Aronsson, L., Y. Huang, P. Parini, M. Korach-Andre, J. Hakansson, J.A. Gustafsson, et al., Decreased fat storage by *Lactobacillus paracasei* is associated with increased levels of angiopoietin-like 4 protein (ANGPTL4). *PLoS One.* 2010; 5(9).
- [63] Tanida, M., J. Shen, K. Maeda, Y. Horii, T. Yamano, Y. Fukushima, et al., High-fat diet-induced obesity is attenuated by probiotic strain *Lactobacillus paracasei* ST11 (NCC2461) in rats. *Obes Res Clin Pract.* 2008; 2(3):I-ii.
- [64] Kobyliak, N., C. Conte, G. Cammarota, A.P. Haley, I. Styriak, L. Gaspar, et al., Probiotics in prevention and treatment of obesity: a critical view. *Nutr*

Metab (Lond). 2016; 13:14.

- [65] Apaijai, N., K. Chinda, S. Palee, S. Chattipakorn, and N. Chattipakorn, Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats. PLoS One. 2014; 9(7):e102374.
- [66] Allain, C.C., L.S. Poon, C.S. Chan, W. Richmond, and P.C. Fu, Enzymatic determination of total serum cholesterol. Clin Chem. 1974; 20(4):470-5.
- [67] Roeschlau, P., E. Bernt, and W. Gruber, Enzymatic determination of total cholesterol in serum. Z Klin Chem Klin Biochem. 1974; 12(5):226.
- [68] Friedewald, W.T., R.I. Levy, and D.S. Fredrickson, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6):499-502.
- [69] Pipatpiboon, N., W. Pratchayasakul, N. Chattipakorn, and S.C. Chattipakorn, PPARgamma agonist improves neuronal insulin receptor function in hippocampus and brain mitochondria function in rats with insulin resistance induced by long term high-fat diets. Endocrinology. 2012; 153(1):329-38.
- [70] Matthews, D.R., J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7):412-9.
- [71] Xiao, S. and L. Zhao, Gut microbiota-based translational biomarkers to prevent metabolic syndrome via nutritional modulation. Fems Microbiology Ecology. 2014; 87(2):303-314.
- [72] Maity, C., A. Adak, T.K. Pathak, B.R. Pati, and K. Chandra Mondal, Study of the cultivable microflora of the large intestine of the rat under varied environmental hyperbaric pressures. J Microbiol Immunol Infect. 2012; 45(4):281-6.

- [73] Lee, D.K., S. Jang, E.H. Baek, M.J. Kim, K.S. Lee, H.S. Shin, et al., Lactic acid bacteria affect serum cholesterol levels, harmful fecal enzyme activity, and fecal water content. *Lipids in Health and Disease*. 2009; 8:21-21.
- [74] Peinnequin, A., C. Mouret, O. Birot, A. Alonso, J. Mathieu, D. Clarencon, et al., Rat pro-inflammatory cytokine and cytokine related mRNA quantification by real-time polymerase chain reaction using SYBR green. *BMC Immunol*. 2004; 5:3.
- [75] Ogden, C.L., S.Z. Yanovski, M.D. Carroll, and K.M. Flegal, The epidemiology of obesity. *Gastroenterology*. 2007; 132(6):2087-102.
- [76] Eckel, R.H., S.M. Grundy, and P.Z. Zimmet, The metabolic syndrome. *Lancet*. 2005; 365(9468):1415-28.
- [77] Musso, G., R. Gambino, and M. Cassader, Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? *Diabetes Care*. 2010; 33(10):2277-84.
- [78] Xiao, S., N. Fei, X. Pang, J. Shen, L. Wang, B. Zhang, et al., A gut microbiota-targeted dietary intervention for amelioration of chronic inflammation underlying metabolic syndrome. *FEMS Microbiol Ecol*. 2014; 87(2):357-67.
- [79] Yin, Y.N., Q.F. Yu, N. Fu, X.W. Liu, and F.G. Lu, Effects of four Bifidobacteria on obesity in high-fat diet induced rats. *World J Gastroenterol*. 2010; 16(27):3394-401.
- [80] Million, M., E. Angelakis, M. Paul, F. Armougom, L. Leibovici, and D. Raoult, Comparative meta-analysis of the effect of Lactobacillus species on weight gain in humans and animals. *Microb Pathog*. 2012; 53(2):100-8.